Evidence map›Paper›PMID 38042696›Full record

ReviewVaccine2024

Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries.

Mary Carol Jennings, Molly Sauer, Chloe Manchester, Heidi M Soeters, Lora Shimp, Terri B Hyde, Umesh Parashar, Craig Burgess, Brian Castro, Iqbal Hossein and 8 more

Abstract readReview
In one paragraph

Review in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mary Carol JenningsDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Molly SauerDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Electronic address: msauer3@jhu.edu.
Chloe ManchesterJSI Research and Training Institute, Arlington, USA.
Heidi M SoetersU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Lora ShimpJSI Research and Training Institute, Arlington, USA.
Terri B HydeU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Umesh ParasharU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Craig BurgessJSI Research and Training Institute, Arlington, USA.
Brian CastroJSI Research and Training Institute, Arlington, USA.
Iqbal HosseinJSI Research and Training Institute, Arlington, USA.
Michel OthepaJSI Research and Training Institute, Arlington, USA.
Daniel C PayneU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Jacqueline E TateU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Jenny WalldorfU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Lois Privor-DummDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Vanessa RichartJSI Research and Training Institute, Arlington, USA.
Mathuram SantoshamDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Rotavirus Accelerated Vaccine Introduction Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the 2009 World Health Organization recommendation that all countries introduce rotavirus vaccines (RVV) into their national immunization programs, just 81 countries had introduced RVV by the end of 2015, leaving millions of children at risk for rotavirus morbidity and mortality. In response, the Rotavirus Accelerated Vaccine Introduction Network (RAVIN) was established in 2016 to provide support to eight Gavi-eligible countries that had yet to make an RVV introduction decision and/or had requested technical assistance with RVV preparations: Afghanistan, Bangladesh, Benin, Cambodia, Democratic Republic of Congo, Lao People's Democratic Republic, Myanmar, and Nepal. During 2016-2020, RAVIN worked with country governments and partners to support evidence-based immunization decision-making, RVV introduction preparation and implementation, and multilateral coordination. By the September 2020 program close-out, five of the eight RAVIN focus countries successfully introduced RVV into their routine childhood immunization programs. We report on the RAVIN approach, describe how the project responded collectively to an evolving RVV product landscape, synthesize common characteristics of the RAVIN country experiences, highlight key lessons learned, and outline the unfinished agenda to inform future new vaccine introduction efforts by countries and global partners.

Indexed as

Immunization ProgramsRotavirus InfectionsRotavirus VaccinesChildDeveloping CountriesHumansRotavirusVaccinationWorld Health OrganizationRotavirus VaccinesGaviImmunizationImplementationPolicyRotavirus

Identifiers

PMID38042696
PMCPMC10733863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.